1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Drs. Chirieac and Hamilton were supported by the Frederick F. Becker Distinguished University Chair in Cancer Research from The University of Texas.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
Article first published online: 17 FEB 2005
DOI: 10.1002/cncr.20916
Copyright © 2005 American Cancer Society
Additional Information
How to Cite
Chirieac, L. R., Swisher, S. G., Ajani, J. A., Komaki, R. R., Correa, A. M., Morris, J. S., Roth, J. A., Rashid, A., Hamilton, S. R. and Wu, T.-T. (2005), Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer, 103: 1347–1355. doi: 10.1002/cncr.20916
- ‡
Drs. Chirieac and Hamilton were supported by the Frederick F. Becker Distinguished University Chair in Cancer Research from The University of Texas.
- §
Fax: (713) 792-4049
Publication History
- Issue published online: 18 MAR 2005
- Article first published online: 17 FEB 2005
- Manuscript Accepted: 3 DEC 2004
- Manuscript Revised: 17 NOV 2004
- Manuscript Received: 20 SEP 2004
Funded by
- Frederick F. Becker Distinguished University Chair in Cancer Research from The University of Texas
- Abstract
- Article
- References
- Cited By
Keywords:
- esophagus;
- residual carcinoma;
- chemoradiation;
- stage;
- prognosis
Abstract
BACKGROUND
In patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent preoperative chemoradiation, it is unclear whether survival was better predicted by pretherapy clinical stage or by posttherapy pathologic stage.
METHODS
The authors studied 235 consecutive patients with pretherapy clinical Stage II, III, or IVA (according to American Joint Committee on Cancer criteria) carcinoma of the esophagus or esophagogastric junction who were treated with chemoradiation followed by esophagectomy. Posttherapy cancer status was classified using pathologic stage and semiquantitative assessment of residual carcinoma. Clinicopathologic features, residual carcinoma status, and pretherapy and posttherapy stage were compared with disease-free and overall survival.
RESULTS
Posttherapy pathologic stage was Stage 0 in 29% of patients, Stage I in 11% of patients, Stage II in 34% of patients, Stage III in 20% of patients, and Stage IV in 6% of patients. Cancer downstaging occurred in 56% of patients. In univariate analysis, disease-free and overall survival were predicted by posttherapy pathologic stage (both with P < 0.001), margin status (P = 0.002 and P = 0.01, respectively), extent of residual carcinoma (both with P < 0.001), and downstaging (both with P = 0.001), but not by age, gender, type of cancer, pretherapy clinical stage, or preoperative regimen. However, in multivariate analysis, disease-free and overall survival were independently predicted by posttherapy pathologic stage (both with P = 0.02). Extent of residual carcinoma was a marginally significant predictor of overall survival (P = 0.04).
CONCLUSIONS
Posttherapy pathologic stage was the best available predictor of outcome for patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent chemoradiation therapy followed by esophagectomy. The findings in the current study supported the concept of downstaging by preoperative therapy. Cancer 2005. © 2005 American Cancer Society.